When you choose dōTERRA®, you are choosing essential oils gently and carefully distilled from plants that have been patiently harvested at the perfect moment by experienced growers from around the world for ideal extract composition and efficacy. Each dōTERRA essential oil is also carefully and thoroughly tested using the strict CPTG Certified Pure Therapeutic Grade® quality protocol.
After giving birth, reaching menopause years or experiencing other hormonal imbalances, it’s not uncommon for women to start losing hair. And while hair loss is a normal process (the American Academy of Dermatology estimates the average person sheds about 50-100 hairs a day), it’s also something that can be remedied by addressing underlying health and hormonal problems.
It’s common for women to experience shedding hair after pregnancy. Usually, this is in response to estrogen levels returning to normal, shedding the extra hair grown during pregnancy. Usually, the hair will return to the same thickness it was before you got pregnant. New moms who are not breastfeeding should consider taking hair growth vitamins post-pregnancy too to balance out their hair growth cycle.
Insulin regulation is also a big factor in hair health, as an imbalance can lead to various hormonal effects. Insulin helps to regulate blood sugar levels, which effects fat storage and hormone balance. Fat storage and hormone balance play a role in hair growth because fat storages will secrete excess estrogen in the body, and can desensitize hormone signals.
Skin infections can cause hair loss at the affected area. One of the more common causes is a fungal infection of the skin, also sometimes referred to as a ringworm. Eyebrow fungus is more likely to be related to a scalp fungus (tinea capitis) and both areas are often affected at the same time. A bacterial infection is another possible cause. Folliculitis for example is a condition where the hair follicle becomes infected usually with bacteria like Staphylococcus aureus. Eventually this can lead to loss of the hair in the infected follicle.
This manifests in childhood with chronic lower eyelid dermatitis and is often associated with other types of allergic disorders.[36,37] The ocular features are eyelid dermatitis, Dennie-Morgan fold (an infraorbital fold or line due to lid edema in atopic dermatitis), keratitis, and a frequent association with keratoconus and cataracts. Loss of lateral third of eyebrows (Hertoghe sign) is seen in atopic dermatitis due to constant scratching and rubbing.
There are numerous diseases that can affect the hair and scalp. Hair loss can be caused by a variety of conditions. Diseases such as alopecia areata, anemia, male/female pattern baldness, and infections of the scalp can all cause significant difficulty and loss of daily well-being. Stanford Dermatology has established a special clinic focusing on the diagnosis and treatment of these disorders of the hair.
A number of skin and hair disorders can lead to eyebrow hair loss and sometimes it may be linked to systemic diseases like lupus. Specific skin and hair disorders that are most likely to lead to eyebrow thinning and hair loss have been discussed below but other conditions like psoriasis may also be involved if it occurs on the eyebrow or forehead. Eyebrow hair loss may occur in people on chemotherapy (cancer medication) and with radiation therapy to the head.
Prostaglandins are modified forms of unsaturated fatty acids–those unsaturated or “essential” fatty acids (EFAs) that are also called Omega fatty acids. These EFAs cannot be produced by your body, but must be absorbed from our food. EFAs are naturally found in nut and seed oils in different compositions. EFAs have been shown to increase prostaglandin production in those with a deficiency (source, again).
While female hair loss may not cause physical pain, it does cause mental anguish. Fortunately, in many cases, female hair loss can be successfully treated with today’s advanced nonsurgical and surgical treatment options. After a diagnosis has been confirmed, Dr. Yaker will create a customized treatment plan depending on one’s hair characteristics, the level of hair loss and the aesthetic goals of the patient.
A new entity variously called as trichodysplasia spinulosa, trichodysplasia of immunosuppression, and cyclosporine-induced folliculodystrophy has been described in immunocompromised patients, usually organ transplant recipients on immunosuppression. It involves the development of alopecia predominantly of the face with indurated spinous papules. There is a profound loss of eyebrows and sometimes eyelashes. The histopathologic picture is that of abnormal follicles with hyperkeratotic infundibula and absence of normal hair shafts. The inner root sheath epithelium showed proliferation in the cells and dystrophic trichohyaline granules. Electron microscopy of skin showed presence of intracellular viral particles. This entity has lately been reported in immunosuppressive states in patients without organ transplantation such as leukemias and lymphoma.[133–136] van der Meijden et al. described the discovery of a new polyoma virus in a patient with trichodysplasia spinulosa. Histopathological examination can reveal the diagnosis. A recent simple pull-test wherein the spicules can be plucked and examined under the microscope for inner root sheath keratinization has been described. Some successful treatments described are cessation of cyclosporine therapy and oral valganciclovir[137,138] and topical cidofovir.
Flutamide is an oral anti-androgen that acts by competitively inhibiting the uptake of androgen and its nuclear binding in target tissues (Varothai and Bergfeld, 2014; Watson Pharma, 2011). It has been shown to be effective for the treatment of FPHL in hyperandrogenic women at a dose of 250 mg per day. One case report showed that treatment with flutamide was effective in a patient who had already failed to improve with spironolactone and minoxidil (Carmina and Lobo, 2003, Yazdabadi and Sinclair, 2011). After 2 years of therapy, 80% of patients were satisfied or highly satisfied with their treatment effect regardless whether they were taking concomitant oral contraceptives (Paradisi et al., 2011). Flutamide can cause hepatotoxicity and serial monitoring of liver function tests is recommended during treatment (Watson Pharma, 2011) even though data from one study on the safety and tolerability of flutamide showed that patient transaminase values returned to normal after treatment was discontinued and that levels did not rise while patients were treated with doses of 62.5 mg or 125 mg. Flutamide is classified as pregnancy category D.
Cyproterone acetate works in several ways. It not only competitively blocks DHT from binding to its receptors at target tissue (Gilman et al., 1990), but it is also a progestogen that lowers testosterone levels by decreasing the release of luteinizing and follicle-stimulating hormones through pituitary-mediated supression (Gilman et al., 1990, Varothai and Bergfeld, 2014). An open intervention study of 80 women who received treatment with spironolactone (200 mg daily) or cyproterone acetate (50 mg daily or 100 mg for 10 days per month if premenopausal) showed that three of four patients demonstrated an improvement or stabilization of their disease with no difference of effect between the therapies received (Sinclair et al., 2005).
Tames and Goldenring described a case of bilateral loss of eyebrows and eyelashes in a patient with AIDS-related complex who had smoked crack cocaine. This has been attributed to hot vapors during the process of smoking, and which therefore caused singeing of the brows and lashes. There was a complete reversal once the patient abstained from cocaine.
When your body goes through something traumatic like child birth, malnutrition, a severe infection, major surgery, or extreme stress, many of the 90 percent or so of the hair in the anagen (growing) phase or catagen (resting) phase can shift all at once into the shedding (telogen) phase. About 6 weeks to three month after the stressful event is usually when the phenomenon called telogen effluvium can begin. It is possible to lose handful of hair at time when in full-blown telogen effluvium. For most who suffer with TE complete remission is probable as long as severely stressful events can be avoided. For some women however, telogen effluvium is a mysterious chronic disorder and can persist for months or even years without any true understanding of any triggering factors or stressors.
Infestation with the mite D. folliculorum which inhabits the eyelashes is well known. Two species are known to inhabit human beings—D. folliculorum and Demodex brevis. It might either be asymptomatic or may cause symptoms of blepharitis. Kemal et al. report an overall prevalence of 27.4% in their study group. Gao et al. have reported a 100% prevalence of the mite when there is cylindrical dandruff. Patients with demodicosis can develop madarosis.
Postpartum hair loss is related to the drop in estrogen experienced after giving birth. During pregnancy, the body has higher levels of estrogen (and progesterone) and estrogen increases hair’s “resting phase,” or the time hair stays on your head before naturally falling out (which is what accounts for the 100 or so hairs that healthy heads shed every day). When estrogen drops after pregnancy, all the hair that had been “resting” starts to shed. Post-pregnancy hair loss is usually temporary, lasting for several months.
What she doesn’t mention is how to regrow your brows after chemo-related brow loss! If you have recently undergone chemotherapy, your brows may be a bit wonky in the beginning, but you still want them, right? They are the frame for your beautiful face. Every October we host a “Buy One Give One for the Cure” campaign, where for every bottle of WINK sold, we donate one to a cancer survivor. If that’s you, shoot us an email so we can get you hooked up.
The first step in treatment is to identify the cause of the hair loss. Then, treat it appropriately. If an internal cause is the culprit, it should be addressed — for example, thyroid medication for thyroid disease or supplements for a nutritional deficiency. External skin conditions are often treated with topical medications, and, once treated, the hair loss usually recovers. I often recommend Latisse as an adjunctive treatment. Though frequently associated with eyelash lengthening, it is a great option for thickening brows. In fact, people with brows that thin with aging (I typically don't see this in women under 50) may want to opt for Latisse.
It is perfectly normal for people to shed 50 to 100 hairs per day. This generally doesn't cause noticeable thinning of scalp hair because new hair is growing in at the same time that hair is shedding. However, hair loss occurs when this hair growth cycle and shedding is disrupted or when the hair follicle becomes destroyed and replaced with scar tissue. Female pattern hair loss (androgenetic alopecia) is the most common form of hair loss in women. This occurs gradually and is caused by genetics (from either side of the family), age, and the action of a specific male hormone, dihydrotestosterone (DHT). This hormone is found in lesser amounts in women and it preys on the hair follicles, preventing them from receiving vital nutrients for proper hair follicle growth, leading to the hairs shrinking, and resulting in a shorter lifespan. Interestingly, DHT does not need to be elevated to generate hair loss. Estrogen, when lowered as commonly seen in menopause, creates a change in the ratio of male to female hormones, giving an edge to these male hormones. Compounded with the sensitivity of DHT to the hair follicles, heredity can affect the age at which a woman begins to lose her hair, as well as the rate of hair loss and the extent of baldness.
Dutasteride is a 5-alpha-reductase inhibitor that binds both types I and II enzymes. Compared with finasteride, its inhibition of type II enzymes is three times more potent; its inhibition of type I enzymes is 100 times more potent (Clark et al., 2004). Dutasteride is not approved for the treatment of FPHL by the FDA, and ongoing studies on the efficacy of the inhibitor are promising but largely focus on male patients (Gupta and Charrette, 2014, Olsen et al., 2006). A study of women after 3 years of therapy showed that dutasteride may be more effective than finasteride in women under 50 years of age as measured by hair thickness (not hair density) at the center and vertex scalp (Boersma et al., 2014). One case report of a 46-year-old female with FPHL showed some response after 6 months of treatment with a dose of 0.5-mg dutasteride daily despite a minimal response to treatment with finasteride and minoxidil (Olszewska and Rudnicka, 2005). Data with regard to the treatment side effects in women is extremely limited. Dutasteride is classified as pregnancy category X because of teratogenicity and should have the same theoretical risk of breast cancer as mentioned in relation to finasteride (Kelly et al., 2016).
Management of madarosis primarily depends upon treatment of the predisposing disorder. Inherited disorders can be identified by the associated clinical features. Establishing the diagnosis is an important prerequisite for the management of madarosis. For this, madarosis can be broadly classified as scarring and non-scarring. In non-scarring madarosis, generally regrowth of hair occurs after treatment of the primary disorder. In disorders such as lepromatous leprosy, though the madarosis is non-scarring, hair regrowth does not occur. In such cases, and in cases of scarring madarosis, hair transplant is essential for cosmetic purposes.
Dr. Kimberly Langdon Cull is a University-trained Obstetrician/Gynecologist with 19-years of clinical experience. She delivered over 2000 babies and specializes in gynecologic diseases such as menstrual disorders, infertility diagnosis and treatment especially pertaining to tubal blockage and polycystic ovarian syndrome (PCOS). Dr. Langdon is the inventor of 6 patent pending medical devices, and attended Ohio State University from 1987-1995 receiving her Medical Doctorate Degree (M.D.) with Honors in Obstetrics and Gynecology.
Every child deserves the opportunity to just be a kid—to fit in and feel normal. Kids experiencing hair loss don’t get that chance. That’s why we offer the Hair Club For Kids® program. Hair Club For Kids provides non-surgical hair replacement services, completely free of charge, to children ages 6-17 who are suffering from hair loss. These services are available at all Hair Club locations throughout North America to help reach as many kids as possible. Call 800-269-7384 for details.